<SEC-DOCUMENT>0001213900-24-076184-index.html : 20240905 <SEC-HEADER>0001213900-24-076184.hdr.sgml : 20240905 <ACCEPTANCE-DATETIME>20240905171825 ACCESSION NUMBER: 0001213900-24-076184 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 36 CONFORMED PERIOD OF REPORT: 20240829 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Material Modifications to Rights of Security Holders ITEM INFORMATION: Changes in Registrant's Certifying Accountant ITEM INFORMATION: Changes in Control of Registrant ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics ITEM INFORMATION: Change in Shell Company Status ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240905 DATE AS OF CHANGE: 20240905 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oruka Therapeutics, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 241282218 BUSINESS ADDRESS: STREET 1: 855 OAK GROVE AVE. STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-606-7910 MAIL ADDRESS: STREET 1: 855 OAK GROVE AVE. STREET 2: SUITE 100 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: ARCA biopharma, Inc. DATE OF NAME CHANGE: 20090128 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 </SEC-HEADER> <DOCUMENT> <TYPE>8-K <SEQUENCE>1 <FILENAME>ea0213193-8k_orukathera.htm <DESCRIPTION>CURRENT REPORT <TEXT> Document 1 - file: ea0213193-8k_orukathera.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.1 <SEQUENCE>2 <FILENAME>ea021319301ex3-1_oruka.htm <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024 <TEXT> Document 2 - file: ea021319301ex3-1_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.2 <SEQUENCE>3 <FILENAME>ea021319301ex3-2_oruka.htm <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024 <TEXT> Document 3 - file: ea021319301ex3-2_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.3 <SEQUENCE>4 <FILENAME>ea021319301ex3-3_oruka.htm <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE AUGUST 29, 2024 <TEXT> Document 4 - file: ea021319301ex3-3_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.4 <SEQUENCE>5 <FILENAME>ea021319301ex3-4_oruka.htm <DESCRIPTION>CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, EFFECTIVE SEPTEMBER 3, 2024 <TEXT> Document 5 - file: ea021319301ex3-4_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.5 <SEQUENCE>6 <FILENAME>ea021319301ex3-5_oruka.htm <DESCRIPTION>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF THE COMPANY, FILED SEPTEMBER 3, 2024 <TEXT> Document 6 - file: ea021319301ex3-5_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.6 <SEQUENCE>7 <FILENAME>ea021319301ex3-6_oruka.htm <DESCRIPTION>AMENDED AND RESTATED BYLAWS OF THE COMPANY <TEXT> Document 7 - file: ea021319301ex3-6_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.8 <SEQUENCE>8 <FILENAME>ea021319301ex3-8_oruka.htm <DESCRIPTION>FORM OF CERTIFICATE OF ELIMINATION OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024 <TEXT> Document 8 - file: ea021319301ex3-8_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.9 <SEQUENCE>9 <FILENAME>ea021319301ex3-9_oruka.htm <DESCRIPTION>FORM OF CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES B NON-VOTING CONVERTIBLE PREFERRED STOCK, EFFECTIVE AUGUST 29, 2024 <TEXT> Document 9 - file: ea021319301ex3-9_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.10 <SEQUENCE>10 <FILENAME>ea021319301ex10-10_oruka.htm <DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 STOCK INCENTIVE PLAN <TEXT> Document 10 - file: ea021319301ex10-10_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.11 <SEQUENCE>11 <FILENAME>ea021319301ex10-11_oruka.htm <DESCRIPTION>ORUKA THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN <TEXT> Document 11 - file: ea021319301ex10-11_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.13 <SEQUENCE>12 <FILENAME>ea021319301ex10-13_oruka.htm <DESCRIPTION>SECOND AMENDMENT TO AMENDED AND RESTATED ORUKA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN, EFFECTIVE AS OF MAY 7, 2024 <TEXT> Document 12 - file: ea021319301ex10-13_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.16 <SEQUENCE>13 <FILENAME>ea021319301ex10-16_oruka.htm <DESCRIPTION>FORM OF EMPLOYEE WARRANT AGREEMENT <TEXT> Document 13 - file: ea021319301ex10-16_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.25 <SEQUENCE>14 <FILENAME>ea021319301ex10-25_oruka.htm <DESCRIPTION>CONSULTING AGREEMENT, EFFECTIVE AS OF AUGUST 30, 2024, BY AND BETWEEN ORUKA THERAPEUTICS, INC. AND JEFF DEKKER <TEXT> Document 14 - file: ea021319301ex10-25_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-14.1 <SEQUENCE>15 <FILENAME>ea021319301ex14-1_oruka.htm <DESCRIPTION>CODE OF BUSINESS CONDUCT AND ETHICS OF ORUKA THERAPEUTICS, INC <TEXT> Document 15 - file: ea021319301ex14-1_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-16.1 <SEQUENCE>16 <FILENAME>ea021319301ex16-1_oruka.htm <DESCRIPTION>LETTER FROM KPMG LLP, DATED SEPTEMBER 5, 2024 <TEXT> Document 16 - file: ea021319301ex16-1_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-21.1 <SEQUENCE>17 <FILENAME>ea021319301ex21-1_oruka.htm <DESCRIPTION>LIST OF SUBSIDIARIES OF ORUKA THERAPEUTICS, INC <TEXT> Document 17 - file: ea021319301ex21-1_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>18 <FILENAME>ea021319301ex99-1_oruka.htm <DESCRIPTION>PRESS RELEASE, ISSUED ON SEPTEMBER 3, 2024 <TEXT> Document 18 - file: ea021319301ex99-1_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>19 <FILENAME>ea021319301ex99-2_oruka.htm <DESCRIPTION>AUDITED FINANCIAL STATEMENT OF ORUKA THERAPEUTICS, INC. AS OF FEBRUARY 6, 2024 <TEXT> Document 19 - file: ea021319301ex99-2_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>20 <FILENAME>ea021319301ex99-3_oruka.htm <DESCRIPTION>UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024 <TEXT> Document 20 - file: ea021319301ex99-3_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.4 <SEQUENCE>21 <FILENAME>ea021319301ex99-4_oruka.htm <DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2024 AND THE PERIOD FROM FEBRUARY 6, 2024 (INCEPTION) TO JUNE 30, 2024 <TEXT> Document 21 - file: ea021319301ex99-4_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.5 <SEQUENCE>22 <FILENAME>ea021319301ex99-5_oruka.htm <DESCRIPTION>UNAUDITED PRO FORMA FINANCIAL STATEMENTS OF ORUKA THERAPEUTICS, INC. AND ARCA BIOPHARMA, INC. AS OF JUNE 30, 2024 AND FOR THE SIX MONTHS ENDED JUNE 30, 2024, AS WELL AS FOR THE YEAR ENDED DECEMBER 31, 2023 <TEXT> Document 22 - file: ea021319301ex99-5_oruka.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>23 <FILENAME>ex14-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 23 - file: ex14-1_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>24 <FILENAME>orka-20240829.xsd <DESCRIPTION>XBRL SCHEMA FILE <TEXT> Document 24 - file: orka-20240829.xsd
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>25 <FILENAME>orka-20240829_def.xml <DESCRIPTION>XBRL DEFINITION FILE <TEXT> Document 25 - file: orka-20240829_def.xml
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>26 <FILENAME>orka-20240829_lab.xml <DESCRIPTION>XBRL LABEL FILE <TEXT> Document 26 - file: orka-20240829_lab.xml
</DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>27 <FILENAME>orka-20240829_pre.xml <DESCRIPTION>XBRL PRESENTATION FILE <TEXT> Document 27 - file: orka-20240829_pre.xml
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>29 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 29 - file: R1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>30 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 30 - file: Financial_Report.xlsx
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 31 - file: Show.js
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 32 - file: report.css
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>34 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 34 - file: FilingSummary.html
Document 34 - RAW XML: FilingSummary.xml
</DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>36 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 36 - file: MetaLinks.json
</DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>37 <FILENAME>0001213900-24-076184-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 37 - file: 0001213900-24-076184-xbrl.zip
</DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>38 <FILENAME>ea0213193-8k_orukathera_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> Document 38 - file: ea0213193-8k_orukathera_htm.html
Document 38 - RAW XML: ea0213193-8k_orukathera_htm.xml
</DOCUMENT> </SEC-DOCUMENT>